Chiral separations of some β-adrenergic agonists and antagonists on AmyCoat column by HPLC

Chirality

Volumn 22, Issue 1, 2010, Pages 24-28

  Ali, Imran ^a   Saleem, Kishwar ^a   Gaitonde, Vinay D ^b   Aboul Enein, Hassan Y ^c   Hussain, Iqbal ^a  

^a JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

^b Prochrome India   (India)

^c NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

adrenergic agonists; adrenergic blockers; AmyCoat chiral stationary phase; Chiral recognition mechanism; Chiral separation

Indexed keywords

ALCOHOL; ALPRENOLOL; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BISOPROLOL; BOPINDOLOL; BUFUROLOL; CARAZOLOL; CELIPROLOL; CIMETEROL; CLENBUTEROL; DIETHYLAMINE; HEPTANE; INDENOLOL; METOPROLOL; NEBIVOLOL; OXPRENOLOL; PRACTOLOL; PROPRANOLOL; TERTALOL; TIMOLOL; UNCLASSIFIED DRUG;

ARTICLE; CHIRALITY; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; VALIDATION STUDY;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; LIMIT OF DETECTION; SPECTROPHOTOMETRY, ULTRAVIOLET; STEREOISOMERISM;

EID: 75449115733     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.20697     Document Type: Article

References (12)

1. FDA's policy statement for the development of new stereoisomeric drugs. Chirality 1992;4:338-340.
2. Aboul-Enein HY, Ali I. Chiral separation by liquid chromatography and related technologies. New York: Marcel Dekker Inc.; 2003.
3. Meyers EH, Jawetz E, Goldheim AA. Review of medical pharmacology, 7th ed. Loss Altos: Lange Medical Publication; 1980. p 95.
4. Walle T, Walle KW. Pharmacokinetic parameters obtained with racemates. TIPS 1986;7:155-158.
5. Schmid MG, Gecse O, Szabo Z, Kilar F, Gubitz G, Ali I, Aboul-Enein HY. Comparetive study of the chiral resolution of β-blockers on cellulose tris-(3,5-dimethylephenyle carbamate) phase in normal and reversed phase mode. J Liq Chromatogr Relat Technol 2001;24:2493-2504.
6. Lee EJ, William KM. Chirality, clinical pharmacokinetic, and pharmacodynamic considerations. Clin Pharmacokinet 1990;18:339-345.
7. Danilewiez JC, Kamp JK. Absolute configuration by asymmetric synthesis of (+)-1-(4-acetamidophenoxy)-3-(isopropylamino)-propan-z-ol (practolol). J Med Chem 1973;16:168-169.
8. Silber B, Holford NHG, Regelman S. Stereoselective disposition and glucuronidation of propranolol in humans. J Pharm Sci 1982;71:699-704.
9. Bode W, Toet AE, Stolker AA, van Ginkel LA, Groen K, Wemer J, de Wildt DJ. Toxicokinetics of a single intravenous dose of rac-propranolol versus optically pure propranolol in the rat. Chirality 1995;7:626-631.
10. Eber O, Buchinger W, Lindner W, Lind P, Rath M, Klima G, Langsteger W, Költringer P. The effect of D- versus L-propranolol in the treatment of hyperthyroidism. Clin Endocrinol (Oxf) 1990;32:363-372.
11. Ali I, Hussain A, Aboul-Enein HY, Bazylak G. Supramolecular systems based HPLC for chiral separation of β-adrenergics and β-adrenolytics in drug discovery schemes. Curr Drug Discov Technol 2007;4:255-274.
12. Ali I, Naim L, Ghanem A, Aboul-Enein HY. Chiral separations of piperidine-2,6-dione analogues on chiralpak IA and chiralpak IB columns by using HPLC. Talanta 2006;69:1013-1017.